Buprenorphine

Generic Name: Buprenorphine

Brand Names: Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₄₁NO_₄

CAS Number: 52485-79-7

Unique Ingredient Identifier: 40D3SCR4GZ

Background: Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...

Indication: Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...

Associated Conditions: Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence

Associated Therapies: -

Clinical Trials

The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder

Phase 4

Terminated

Conditions: Opioid-use Disorder

Interventions: Drug: Buprenorphine

First Posted Date: 2021-07-29

Last Posted Date: 2024-12-13

Lead Sponsor: MaineHealth

Target Recruit Count: 12

Registration Number: NCT04981678

Locations: 🇺🇸
Maine Medical Center, Portland, Maine, United States

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Buprenorphine
Drug: Tramadol
Device: Oral Mucositis (OM) Pain App

First Posted Date: 2021-02-12

Last Posted Date: 2024-05-16

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 20

Registration Number: NCT04752384

Locations: 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

Phase 2

Completed

Conditions: Opioid Dependence
End Stage Renal Disease
Chronic Pain

Interventions: Behavioral: Pain Coping Skills Training (PCST)
Drug: Buprenorphine

First Posted Date: 2020-10-01

Last Posted Date: 2024-06-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 643

Registration Number: NCT04571619

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 13 locations

Virginia Opioid Treatment-Emergency Department

Phase 3

Withdrawn

Conditions: Opioid Use Disorder

Interventions: Drug: SUBLOCADE

First Posted Date: 2020-08-24

Last Posted Date: 2021-02-12

Lead Sponsor: Virginia Commonwealth University

Registration Number: NCT04523792

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Phase 2

Not yet recruiting

Conditions: Opioid Dependence

Interventions: Drug: Vivitrol
Drug: Brixadi

First Posted Date: 2020-07-01

Last Posted Date: 2024-11-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 200

Registration Number: NCT04454411

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Phase 4

Recruiting

Conditions: Major Depressive Disorder
Depression

Interventions: Drug: Buprenorphine
Drug: Naltrexone
Drug: Oral Placebo
Drug: IM Placebo
Device: Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.

First Posted Date: 2020-02-19

Last Posted Date: 2024-07-03

Lead Sponsor: Marta Peciña, MD PhD

Target Recruit Count: 120

Registration Number: NCT04276259

Locations: 🇺🇸
Bellefield Tower, Pittsburgh, Pennsylvania, United States

Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

Phase 4

Withdrawn

Conditions: Opioid Use Disorder

Interventions: Drug: buprenorphine

First Posted Date: 2019-12-26

Last Posted Date: 2020-10-14

Lead Sponsor: Ohio State University

Registration Number: NCT04212065

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States

Opiate Suicide Study in Patients With Major Depression

Phase 3

Recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: Ketamine
Drug: Buprenorphine
Drug: Placebo oral tablet

First Posted Date: 2019-10-04

Last Posted Date: 2024-07-11

Lead Sponsor: Stanford University

Target Recruit Count: 60

Registration Number: NCT04116528

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms

Phase 4

Conditions: Opioid-use Disorder
Opioid Use Disorder, Mild

Interventions: Drug: Buprenorphine
Drug: Buprenorphine/naloxone

First Posted Date: 2019-09-16

Last Posted Date: 2019-09-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 76

Registration Number: NCT04091009

SUBLOCADE Rapid Initiation Extension Study

Phase 4

Completed

Conditions: Opioid Use Disorder, Severe
Opioid Use Disorder, Moderate

Interventions: Drug: Sublocade

First Posted Date: 2019-08-19

Last Posted Date: 2021-02-11

Lead Sponsor: Indivior Inc.

Target Recruit Count: 17

Registration Number: NCT04060654

Locations: 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy